[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112015023105A8 - construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo. - Google Patents

construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo.

Info

Publication number
BR112015023105A8
BR112015023105A8 BR112015023105A BR112015023105A BR112015023105A8 BR 112015023105 A8 BR112015023105 A8 BR 112015023105A8 BR 112015023105 A BR112015023105 A BR 112015023105A BR 112015023105 A BR112015023105 A BR 112015023105A BR 112015023105 A8 BR112015023105 A8 BR 112015023105A8
Authority
BR
Brazil
Prior art keywords
peptide
constructs
immunogen
individual
alzheimer
Prior art date
Application number
BR112015023105A
Other languages
English (en)
Other versions
BR112015023105A2 (pt
Inventor
Yi Wang Chang
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of BR112015023105A2 publication Critical patent/BR112015023105A2/pt
Publication of BR112015023105A8 publication Critical patent/BR112015023105A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

abstract the present disclosure is directed to individual aß peptide immunogen constructs, peptide compositions comprising these aß peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these aß peptide immunogen constructs, with the individual aß peptide immunogen constructs having the n-terminus of the aß peptide as the b cell (b) epitopes linked through spacer residue(s) to heterologous t helper cell (th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the n-terminus of the aß peptide offering protective immune responses to patients at risk for, or with, alzheimer's disease. tradução do resumo resumo título: vacina peptídica para prevenção e imunoterapia de demência advinda de alzheimer a presente invenção refere-se a construtos peptídeo imunógeno aß individuais, composições peptídicas compreendendo estes construtos peptídeo imunógeno aß e misturas dos mesmos, composições farmacêuticas incluindo formulações de vacina compreendendo esses construtos peptídeo imunógeno aß, com os construtos peptídeo imunógeno aß individuais tendo o n-terminal do peptídeo aß, tal como os epítopos da célula b (b) ligados através de resíduo(s) espaçador heterólogo para epítopos (th) de células t helper derivados de proteínas patogênicas que atuam em conjunto para estimular a produção de anticorpos altamente específicos direcionados contra o n-terminal do peptídeo aß oferecendo respostas imunes protetoras para pacientes em risco de, ou com, a doença de alzheimer.
BR112015023105A 2013-03-15 2013-04-23 construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo. BR112015023105A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/843,883 US9102752B2 (en) 2013-03-15 2013-03-15 Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
PCT/US2013/037865 WO2014143087A1 (en) 2013-03-15 2013-04-23 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Publications (2)

Publication Number Publication Date
BR112015023105A2 BR112015023105A2 (pt) 2017-11-21
BR112015023105A8 true BR112015023105A8 (pt) 2018-01-23

Family

ID=51527985

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023105A BR112015023105A8 (pt) 2013-03-15 2013-04-23 construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo.

Country Status (19)

Country Link
US (4) US9102752B2 (pt)
EP (1) EP2968485B1 (pt)
JP (3) JP6208319B2 (pt)
KR (2) KR20180132962A (pt)
CN (2) CN105228644B (pt)
AU (3) AU2013381835A1 (pt)
BR (1) BR112015023105A8 (pt)
CA (1) CA2906313A1 (pt)
DK (1) DK2968485T3 (pt)
ES (1) ES2800028T3 (pt)
HK (1) HK1212600A1 (pt)
IL (2) IL241597B (pt)
MX (2) MX364689B (pt)
PT (1) PT2968485T (pt)
RU (1) RU2696566C2 (pt)
SG (1) SG11201507669YA (pt)
TW (1) TWI561529B (pt)
WO (1) WO2014143087A1 (pt)
ZA (2) ZA201507526B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
WO2015157283A1 (en) * 2014-04-07 2015-10-15 Merganser Biotech Llc Hepdicin mimetic peptides and uses thereof
EP3409130B1 (en) 2016-01-27 2020-11-25 Industry-Academic Cooperation Foundation Gyeongsang National University Composition for preventing, alleviating or treating neurological disorders, containing, as active ingredient, novel peptide activating adiponectin receptors
JP7161401B2 (ja) * 2016-04-14 2022-10-26 公益財団法人神戸医療産業都市推進機構 アミロスフェロイド（ａｓｐｄ）様構造体及び医薬組成物
CN106565847B (zh) * 2016-10-26 2020-12-01 清华大学 化合物、多肽及其用途
KR20240150813A (ko) * 2017-06-16 2024-10-16 유나이티드 뉴로사이언스 알파-시뉴클린 단백질의 c-말단부로부터의 펩티드 면역원 및 시뉴클레인병증 치료를 위한 그의 제형화
BR112020008202A2 (pt) 2017-10-27 2020-10-27 United Neuroscience construções de imunógeno de peptídeo tau
JP7250032B2 (ja) * 2017-12-11 2023-03-31 ユービーアイ アイピー ホールディングス アトピー性皮膚炎の治療及び／または予防のためのｉｌ－３１のペプチド免疫原ならびにその製剤
CN111565801B (zh) * 2017-12-31 2023-11-10 美国联合生物医学公司 用于IgE介导过敏性疾病治疗的靶向膜结合型IgE的肽免疫原及其剂型
US20200400688A1 (en) * 2018-02-13 2020-12-24 Cedars-Sinai Medical Center Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
BR112020020660A2 (pt) 2018-04-10 2021-03-02 Ac Immune Sa vacinas terapêuticas anti-abeta
EP3790581A4 (en) * 2018-05-04 2022-06-22 UBI IP Holdings ARTIFICIAL PROMISCUOUS T-HELPER CELL EPITOPS THAT ENABLE TARGETED ANTIBODY PRODUCTION WITH LIMITED T-CELL INFLAMMATORY RESPONSE
TWI676635B (zh) * 2018-06-15 2019-11-11 英屬開曼群島商聯腦科學公司 α－突觸核蛋白Ｃ端胜肽免疫原及其用於治療突觸核蛋白疾病的配方
AU2019354291A1 (en) * 2018-10-01 2021-05-06 United Neuroscience Peptide immunogen constructs directed against dipeptide repeat proteins from C9ORF72
KR20210104745A (ko) * 2018-12-19 2021-08-25 유나이티드 바이오메디칼 인크. 합성 펩티드 면역원에 대한 면역 자극제로서 인공 무차별적 t 헬퍼 세포 에피토프
CA3125286A1 (en) * 2018-12-28 2020-07-02 United Biomedical, Inc. Peptide immunogens targeting interleukin 6 (il-6) and formulations thereof for immunotherapy of diseases impacted by il-6 dysregulation
BR112021012906A2 (pt) * 2018-12-31 2021-12-28 United Neuroscience Ltd Imunógenos de peptídeo que têm como alvo peptídeo relacionado ao gene da calcitonina (cgrp) e formulações dos mesmos para prevenção e tratamento de enxaqueca
CN110759987B (zh) * 2019-10-29 2021-06-08 中国人民解放军军事科学院军事医学研究院 构象特异性的重组Aβ1-42样寡聚体抗原、其制备方法和应用
MX2022009144A (es) * 2020-01-23 2022-08-22 United Biomedical Inc Inmunogenos peptidicos dirigidos al peptido activador de adenilato ciclasa hipofisaria (pacap) y formulaciones de los mismos para la prevencion y el tratamiento de migra?a.
KR20230016164A (ko) 2020-03-10 2023-02-01 라이프아크 시클릭 펩티드
EP4247397A4 (en) 2020-11-17 2024-11-06 Iliad Biotechnologies Llc TREATMENT AND PREVENTION OF NEUROPATHOLOGY ASSOCIATED WITH NEURODEGENERATIVE DISEASES
EP4307988A1 (en) * 2021-03-16 2024-01-24 NeuroVision Imaging, Inc. Biofluid-based methods for diagnosing alzheimer's disease-associated conditions
US20240358805A1 (en) * 2021-08-30 2024-10-31 The Brigham And Women's Hospital, Inc. Methods and materials to treat neurodegenerative disease
EP4445910A1 (en) 2021-12-08 2024-10-16 Osaka University Vaccine composition for inducing anti-il-23 antibody
MX2024010451A (es) 2022-02-28 2024-09-18 Tridem Bioscience Gmbh & Co Kg Conjugado que consiste de o que comprende al menos un beta-glucano o un manano.
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN115417915B (zh) * 2022-11-03 2023-02-24 北京引正基因科技有限公司 多肽载体及其应用
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1994028412A1 (en) 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
EP0725838A4 (en) 1993-10-26 1997-02-26 United Biomedical Inc STRUCTURED SYNTHETIC ANTIGAN BANKS AS DIAGNOSTICS, VACCINE AND THERAPEUTIC AGENTS
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
CA2393763A1 (en) 1999-12-08 2001-06-14 Mindset Biopharmaceuticals (Usa), Inc. Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US20030083277A1 (en) * 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1523499A2 (en) * 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005072777A2 (en) * 2004-01-28 2005-08-11 Curix Aps Conjugates of amyloid proteins as vaccines for amyloid-related diseases
WO2007097251A1 (ja) * 2006-02-22 2007-08-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo 抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン
WO2007096076A2 (en) * 2006-02-24 2007-08-30 Chiesi Farmaceutici S.P.A. Anti-amyloid immunogenic compositions, methods and uses
WO2008021296A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of alzheimer's disease
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
WO2010035261A2 (en) * 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
US9067981B1 (en) * 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8916387B2 (en) * 2010-10-28 2014-12-23 Jonas Nilsson Diagnosis and treatment of Alzheimer's disease
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type

Also Published As

Publication number Publication date
MX364689B (es) 2019-05-06
MX2019005268A (es) 2019-07-01
IL241597B (en) 2020-07-30
ZA201507526B (en) 2019-12-18
CN108794615A (zh) 2018-11-13
CN105228644A (zh) 2016-01-06
ES2800028T3 (es) 2020-12-23
PT2968485T (pt) 2020-06-26
RU2015142996A (ru) 2017-04-24
US9102752B2 (en) 2015-08-11
JP2019196397A (ja) 2019-11-14
EP2968485B1 (en) 2020-03-04
US20160068581A1 (en) 2016-03-10
AU2017203425A1 (en) 2017-06-08
TW201434478A (zh) 2014-09-16
SG11201507669YA (en) 2015-10-29
ZA201906683B (en) 2023-04-26
CN105228644B (zh) 2018-07-13
JP2017226646A (ja) 2017-12-28
US20180244739A1 (en) 2018-08-30
DK2968485T3 (da) 2020-06-08
US20190194280A1 (en) 2019-06-27
AU2013381835A1 (en) 2015-10-08
IL265910A (en) 2019-06-30
EP2968485A4 (en) 2016-09-07
JP6784646B2 (ja) 2020-11-11
WO2014143087A1 (en) 2014-09-18
RU2019123453A (ru) 2019-09-10
JP6208319B2 (ja) 2017-10-04
AU2019246916A1 (en) 2019-10-31
AU2017203425B2 (en) 2019-07-11
US20140271690A1 (en) 2014-09-18
EP2968485A1 (en) 2016-01-20
HK1212600A1 (zh) 2016-06-17
JP2016513638A (ja) 2016-05-16
RU2696566C2 (ru) 2019-08-05
BR112015023105A2 (pt) 2017-11-21
KR101926030B1 (ko) 2018-12-10
CA2906313A1 (en) 2014-09-18
MX2015013235A (es) 2016-04-04
KR20150132396A (ko) 2015-11-25
TWI561529B (en) 2016-12-11
KR20180132962A (ko) 2018-12-12

Similar Documents

Publication Publication Date Title
BR112015023105A8 (pt) construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo.
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
DK1968632T3 (da) Forbedret influenzavaccine
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
BR112015020885A2 (pt) polipeptídeos de ligação hiperglicosilados
GT201200271A (es) Proteínas que se unen al tnf-a
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112014020019A2 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
BR112016015422A2 (pt) formulações de vacina de frasco único
BR112015032713A2 (pt) composto; composição terapêutica; composição farmacêutica; método para tratar o câncer em um paciente em necessidade; e método para induzir anticorpos em um animal ou um humano para a finalidade de criar anticorpos monoclonais para usos terapêuticos ou diagnósticos
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
BR112018016912A2 (pt) novo antígeno para uso na vacina contra malária
BR112015014727B8 (pt) Composição imunogênica, vacina, e, uso de uma composição imunogênica
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
BR112016017242A2 (pt) Vetores lentivirais para gerar respostas imunes contra o vírus linfotrópico-t humano do tipo 1
BR112015023402A2 (pt) Proteínas sintéticas de automontagem
IN2014DN09445A (pt)
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
MX2019007924A (es) Vacunas contra la influenza.
CL2013002829A1 (es) Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]